Roche collaborates with Aposense for imaging apoptosis

Manjula Puthenedam, PhD, | | Health Imaging | Molecular Imaging
Aposense has signed a collaboration agreement with Roche to use Aposense’s EarliTest for imaging apoptosis (programmed cell death) in oncology clinical trials.

EarliTest comprises the ML-10 imaging agent for imaging apoptosis with PET and dedicated image analysis software. Under the terms of the non-exclusive agreement, Roche will fund the clinical trials and pay Aposense certain license and milestone fees, in undisclosed amounts.

Aposense, based in Petach-Tikva, Israel added that EarliTest is designed to image tumor response early during treatment and has the potential to accelerate drug development by providing feedback on the biological effect of treatment very early on.

Manjula Puthenedam, PhD,

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services.